Professor Ilaria Bellantuono

MD, PhD

Clinical Medicine, School of Medicine and Population Health

Professor of Musculoskeletal Ageing

i.bellantuono@sheffield.ac.uk
+44 114 215 9037

DU33, D Floor, The Medical School

Full contact details

Professor Ilaria Bellantuono
Clinical Medicine, School of Medicine and Population Health
DU33, D Floor
The Medical School
Beech Hill Road
Sheffield
S10 2RX

Profile

For enquiries please contact - ClinMed-Operational@sheffield.ac.uk

I am the Co-Director of the Healthy Lifespan Institute, one of the 4 flagship Institutes at the University of Sheffield.

I am medically qualified but no longer clinically active. After my PhD in the Department of Experimental Haematology, Paterson Institute for Cancer Research, at the University of Manchester on gene therapy in hematopoietic stem cells, I decided I wanted to focus all my efforts on research. I undertook post-doctoral training in the Department of Immunology, Hammersmith Hospital, Imperial College, working on leukaemia stem cells and ways to harness the immune system to eliminate them. Here I also developed an interest in bone marrow stromal stem cells.

This area of research expanded in subsequent years at the University of Manchester, where I was particularly interested in understanding how stem cells age and impact on the function of blood and bone. I was appointed Lecturer at the University of Sheffield, I am currently Professor in Musculoskeletal Ageing and very recently I was appointed to lead the Healthy Lifespan Institute.

Research interests

The focus of my research is on ways to reduce the onset of multiple age-related disease and frailty by preventing or reversing the ageing using medicinal drugs (geroprotectors). My primary interest is in the diseases of the musculoskeletal system such as osteoporosis and osteoarthritis. I work closely with many colleagues and experts in different age-related diseases to identify common mechanisms (DNA repair and senescence) involved in driving ageing and compounds which target those mechanisms and are able to benefit more than one disease at the same time.

I am very much interested in how we can design clinical trials to test geroprotectors to prevent multimorbidity and frailty. For this, I have worked with Industrial partners and expert in regulatory affairs to reach consensus at the European level.and our roadmap is here. (Bellantuono I. Find drugs that delay many diseases of old age. Nature 2018).

Current projects:

Understanding the role cellular senescence in bone and joint and testing of geroprtoectors for skeletal health
Identification and testing of interventions able to delay ageing and improve healthspan in line with clinical translation
Development of new tools to screen new senolytics

Publications

Show: Featured publications All publications

Featured publications

Journal articles

Morsli S & Bellantuono I (2021) The use of geroprotectors to prevent multimorbidity: Opportunities and challenges. Mechanisms of Ageing and Development, 193, 111391-111391.
Cox LS, Bellantuono I, Lord JM, Sapey E, Mannick JB, Partridge L, Gordon AL, Steves CJ & Witham MD (2020) Tackling immunosenescence to improve COVID-19 outcomes and vaccine response in older adults. The Lancet Healthy Longevity, 1(2), e55-e57. View this article in WRRO
Bellantuono I, de Cabo R, Ehninger D, Di Germanio C, Lawrie A, Miller J, Mitchell SJ, Navas-Enamorado I, Potter PK, Tchkonia T , Trejo JL et al (2020) A toolbox for the longitudinal assessment of healthspan in aging mice. Nature Protocols, 15(2), 540-574.
Trendelenburg AU, Scheuren AC, Potter P, Müller R & Bellantuono I (2019) Geroprotectors: A role in the treatment of frailty. Mechanisms of Ageing and Development, 180, 11-20.
Schosserer M, Banks G, Dogan S, Dungel P, Fernandes A, Presen DM, Matheu A, Osuchowski M, Potter P, Sanfeliu C , Tuna BG et al (2019) Modelling physical resilience in ageing mice. Mechanisms of Ageing and Development, 177, 91-102. View this article in WRRO
Bellantuono I (2018) Find drugs that delay many diseases of old age. Nature, 554(7692), 293-295.
Misra J, Mohanty ST, Madan S, Fernandes JA, Hal Ebetino F, Russell RGG & Bellantuono I (2016) Zoledronate Attenuates Accumulation of DNA Damage in Mesenchymal Stem Cells and Protects Their Function. STEM CELLS, 34(3), 756-767. View this article in WRRO
Dudek M, Gossan N, Yang N, Im H-J, Ruckshanthi JPD, Yoshitane H, Li X, Jin D, Wang P, Boudiffa M , Bellantuono I et al (2016) The chondrocyte clock gene Bmal1 controls cartilage homeostasis and integrity. Journal of Clinical Investigation, 126(1), 365-376.

All publications

Journal articles

Bellantuono I, Mortiboys H, Rocha E, Chamoli M, Chinta SJ, Andersen JK, Wallis R, Bezard E, Goldberg M, Greenamyre T , Hirst W et al (2023) Aging, Parkinson’s disease, and models: what are the challenges?. Aging Biology, 1, 1-30. View this article in WRRO
Oliviero S, Millard E, Chen Z, Rayson A, Roberts BC, Ismail HMS, Bellantuono I & Dall’Ara E (2023) Accuracy of in vivo microCT imaging in assessing the microstructural properties of the mouse tibia subchondral bone. Frontiers in Endocrinology, 13.
Oliviero S, Cheong VS, Roberts BC, Orozco Diaz CA, Griffiths W, Bellantuono I & Dall’Ara E (2022) Reproducibility of densitometric and biomechanical assessment of the mouse tibia from in vivo micro-CT images. Frontiers in Endocrinology, 13.
Rayson A, Boudiffa M, Naveed M, Griffin J, Dall’Ara E & Bellantuono I (2022) Geroprotectors and skeletal health : beyond the headlines. Frontiers in Cell and Developmental Biology, 10. View this article in WRRO
Soriano‐Arroquia A, Gostage J, Xia Q, Bardell D, McCormick R, McCloskey E, Bellantuono I, Clegg P, McDonagh B & Goljanek‐Whysall K (2021) miR‐24 and its target gene Prdx6 regulate viability and senescence of myogenic progenitors during aging. Aging Cell, 20(10).
Bellantuono I & Marengoni A (2021) What researchers on ageing should know about multimorbidity, geroprotectors and artificial intelligence. Mechanisms of Ageing and Development, 195, 111453-111453.
Morsli S & Bellantuono I (2021) The use of geroprotectors to prevent multimorbidity: Opportunities and challenges. Mechanisms of Ageing and Development, 193, 111391-111391.
Oliviero S, Owen R, Reilly GC, Bellantuono I & Dall'Ara E (2020) Optimization of the failure criterion in micro-Finite Element models of the mouse tibia for the non-invasive prediction of its failure load in preclinical applications. Journal of the Mechanical Behavior of Biomedical Materials. View this article in WRRO
Cox LS, Bellantuono I, Lord JM, Sapey E, Mannick JB, Partridge L, Gordon AL, Steves CJ & Witham MD (2020) Tackling immunosenescence to improve COVID-19 outcomes and vaccine response in older adults. The Lancet Healthy Longevity, 1(2), e55-e57. View this article in WRRO
Wyld L, Bellantuono I, Tchkonia T, Morgan J, Turner O, Foss F, George J, Danson S & Kirkland JL (2020) Senescence and cancer : a review of clinical implications of senescence and senotherapies. Cancers, 12(8). View this article in WRRO
Bellantuono I, de Cabo R, Ehninger D, Di Germanio C, Lawrie A, Miller J, Mitchell SJ, Navas-Enamorado I, Potter PK, Tchkonia T , Trejo JL et al (2020) A toolbox for the longitudinal assessment of healthspan in aging mice. Nature Protocols, 15(2), 540-574.
Trendelenburg AU, Scheuren AC, Potter P, Müller R & Bellantuono I (2019) Geroprotectors: A role in the treatment of frailty. Mechanisms of Ageing and Development, 180, 11-20.
Schosserer M, Banks G, Dogan S, Dungel P, Fernandes A, Presen DM, Matheu A, Osuchowski M, Potter P, Sanfeliu C , Tuna BG et al (2019) Modelling physical resilience in ageing mice. Mechanisms of Ageing and Development, 177, 91-102. View this article in WRRO
Bellantuono I, Chen Z, Slack C, Cordero J & Zeidler M (2018) ZOLEDRONATE EXTENDS LIFESPAN AND HEALTHSPAN IN VIVO. Innovation in Aging, 2(suppl_1), 545-545.
Esapa CT, Piret SE, Nesbit MA, Thomas GP, Coulton LA, Gallagher OM, Simon MM, Kumar S, Mallon A-M, Bellantuono I , Brown MA et al (2018) An N‐Ethyl‐N‐Nitrosourea (ENU) Mutagenized Mouse Model for Autosomal Dominant Nonsyndromic Kyphoscoliosis Due to Vertebral Fusion. JBMR Plus, 2(3), 154-163. View this article in WRRO
Bellantuono I (2018) Find drugs that delay many diseases of old age. Nature, 554(7692), 293-295.
Lu Y, Boudiffa M, Dall'Ara E, Yue L, Bellantuono I & Viceconti M (2017) Longitudinal effects of Parathyroid Hormone treatment on morphological, densitometric and mechanical properties of mouse tibia. Journal of the Mechanical Behavior of Biomedical Materials, 75, 244-251. View this article in WRRO
Bellantuono I & Potter PK (2016) Modelling ageing and age-related disease. Drug Discovery Today: Disease Models, 20, 27-32. View this article in WRRO
Bellantuono I & Gonos S (2016) MouseAge: Leading the way in the development of geroprotectors in Europe. Mechanisms of Ageing and Development, 160, 32-33.
Figueira I, Fernandes A, Mladenovic A, Lopez-Contreras A, Henriques CM, Selman C, Ferreiro E, Gonos ES, Trejo JL, Misra J , Rasmussen LJ et al (2016) Interventions for age-related diseases: Shifting the paradigm. Mechanisms of Ageing and Development, 160, 69-92. View this article in WRRO
Wells SE & Bellantuono I (2016) Building for the future: essential infrastructure for rodent ageing studies. Mammalian Genome, 27(7), 440-444. View this article in WRRO
Lu Y, Boudiffa M, Dall'Ara E, Bellantuono I & Viceconti M (2016) Development of a protocol to quantify local bone adaptation over space and time: Quantification of reproducibility. Journal of Biomechanics, 49(10), 2095-2099. View this article in WRRO
Jackson SJ, Andrews N, Ball D, Bellantuono I, Gray J, Hachoumi L, Holmes A, Latcham J, Petrie A, Potter P , Rice A et al (2016) Does age matter? The impact of rodent age on study outcomes. Laboratory Animals. View this article in WRRO
Misra J, Mohanty ST, Madan S, Fernandes JA, Hal Ebetino F, Russell RGG & Bellantuono I (2016) Zoledronate Attenuates Accumulation of DNA Damage in Mesenchymal Stem Cells and Protects Their Function. STEM CELLS, 34(3), 756-767. View this article in WRRO
Dudek M, Gossan N, Yang N, Im H-J, Ruckshanthi JPD, Yoshitane H, Li X, Jin D, Wang P, Boudiffa M , Bellantuono I et al (2016) The chondrocyte clock gene Bmal1 controls cartilage homeostasis and integrity. Journal of Clinical Investigation, 126(1), 365-376.
Lu Y, Boudiffa M, Dall'Ara E, Bellantuono I & Viceconti M (2015) Evaluation of in-vivo measurement errors associated with micro-computed tomography scans by means of the bone surface distance approach. Medical Engineering & Physics, 37(11), 1091-1097. View this article in WRRO
Nye G, Lightfoot A, Sakellariou G, Boudiffa M, Bellantuono I, Brooks S, Richardson A, Jackson M, Van Remmen H, Jeffery N & McArdle A (2014) Musculoskeletal changes in superoxide dismutase 1 null mice (1153.5). The FASEB Journal, 28.
Duran AL, Potter P, Wells S, Kirkwood T, von Zglinicki T, McArdle A, Scudamore C, Meng Q-J, de Haan G, Corcoran A & Bellantuono I (2013) Shared Ageing Research Models (ShARM): a new facility to support ageing research.. Biogerontology, 14(6), 789-794. View this article in WRRO
Loh NY, Bentley L, Dimke H, Verkaart S, Tammaro P, Gorvin CM, Stechman MJ, Ahmad BN, Hannan FM, Piret SE , Evans H et al (2013) Autosomal dominant hypercalciuria in a mouse model due to a mutation of the epithelial calcium channel, TRPV5.. PLoS One, 8(1), e55412. View this article in WRRO
Mohanty ST & Bellantuono I (2013) Intra-femoral injection of human mesenchymal stem cells. Methods in Molecular Biology, 976, 131-141.
Mohanty ST & Bellantuono I (2013) Intra-femoral injection of human mesenchymal stem cells.. Methods Mol Biol, 976, 131-141.
Boddy SL, Chen W, Romero-Guevara R, Kottam L, Bellantuono I & Rivolta MN (2012) Inner ear progenitor cells can be generated in vitro from human bone marrow mesenchymal stem cells.. Regen Med, 7(6), 757-767.
Mohanty ST, Cairney CJ, Chantry AD, Madan S, Fernandes JA, Howe SJ, Moore HD, Thompson MJ, Chen B, Thrasher A , Keith WN et al (2012) A small molecule modulator of prion protein increases human mesenchymal stem cell lifespan, ex vivo expansion, and engraftment to bone marrow in NOD/SCID mice.. Stem Cells, 30(6), 1134-1143.
Bellantuono I, Sanguinetti G & Keith WN (2012) Progeroid syndromes: models for stem cell aging?. Biogerontology, 13(1), 63-75.
Gambardella A, Nagaraju CK, O'Shea PJ, Mohanty ST, Kottam L, Pilling J, Sullivan M, Djerbi M, Koopmann W, Croucher PI & Bellantuono I (2011) Glycogen synthase kinase-3α/β inhibition promotes in vivo amplification of endogenous mesenchymal progenitors with osteogenic and adipogenic potential and their differentiation to the osteogenic lineage.. J Bone Miner Res, 26(4), 811-821.
Mohanty ST, Kottam L, Gambardella A, Nicklin MJ, Coulton L, Hughes D, Wilson AG, Croucher PI & Bellantuono I (2010) Alterations in the self-renewal and differentiation ability of bone marrow mesenchymal stem cells in a mouse model of rheumatoid arthritis.. Arthritis Res Ther, 12(4), R149. View this article in WRRO
Holmes DK, Bellantuono I, Walkinshaw SA, Alfirevic Z, Johnston TA, Subhedar NV, Chittick R, Swindell R & Wynn RF (2009) Telomere length dynamics differ in foetal and early post-natal human leukocytes in a longitudinal study.. Biogerontology, 10(3), 279-284.
Cairney CJ, Sanguinetti G, Ranghini E, Chantry AD, Nostro MC, Bhattacharyya A, Svendsen CN, Keith WN & Bellantuono I (2009) A systems biology approach to Down syndrome: identification of Notch/Wnt dysregulation in a model of stem cells aging.. Biochim Biophys Acta, 1792(4), 353-363.
Bellantuono I, Aldahmash A & Kassem M (2009) Aging of marrow stromal (skeletal) stem cells and their contribution to age-related bone loss.. Biochim Biophys Acta, 1792(4), 364-370.
Suzuki M, McHugh J, Tork C, Shelley B, Hayes A, Bellantuono I, Aebischer P & Svendsen CN (2008) Direct muscle delivery of GDNF with human mesenchymal stem cells improves motor neuron survival and function in a rat model of familial ALS.. Mol Ther, 16(12), 2002-2010.
Corradi-Perini C, Southgate TD, Besley GT, Cooper A, Deakin JA, Wraith JE, Fairbairn LJ, Wynn RF & Bellantuono I (2008) Retrovirally-mediated genetic correction of mesenchymal stem cells from patients affected by mucopolysaccharidosis type II (Hunter Syndrome). GENE THER MOL BIOL, 12B, 167-174.
Bellantuono I & Keith WN (2007) Stem cell ageing: does it happen and can we intervene?. Expert Rev Mol Med, 9(31), 1-20.
Holmes DK, Bates N, Murray M, Ladusans EJ, Morabito A, Bolton-Maggs PHB, Johnston TA, Walkenshaw S, Wynn RF & Bellantuono I (2006) Hematopoietic progenitor cell deficiency in fetuses and children affected by Down's syndrome.. Exp Hematol, 34(12), 1611-1615.
Gillmore R, Xue S-A, Holler A, Kaeda J, Hadjiminas D, Healy V, Dina R, Parry SC, Bellantuono I, Ghani Y , Coombes RC et al (2006) Detection of Wilms' tumor antigen--specific CTL in tumor-draining lymph nodes of patients with early breast cancer.. Clin Cancer Res, 12(1), 34-42.
Baxter MA, Wynn RF, Schyma L, Holmes DK, Wraith JE, Fairbairn LJ & Bellantuono I (2005) Marrow stromal cells from patients affected by MPS I differentially support haematopoietic progenitor cell development.. J Inherit Metab Dis, 28(6), 1045-1053.
Wynn RF, Hart CA, Corradi-Perini C, O'Neill L, Evans CA, Wraith JE, Fairbairn LJ & Bellantuono I (2004) A small proportion of mesenchymal stem cells strongly expresses functionally active CXCR4 receptor capable of promoting migration to bone marrow.. Blood, 104(9), 2643-2645.
Bellantuono I (2004) Haemopoietic stem cells.. Int J Biochem Cell Biol, 36(4), 607-620.
Baxter MA, Wynn RF, Jowitt SN, Wraith JE, Fairbairn LJ & Bellantuono I (2004) Study of telomere length reveals rapid aging of human marrow stromal cells following in vitro expansion.. Stem Cells, 22(5), 675-682.
Dong R, Cwynarski K, Entwistle A, Marelli-Berg F, Dazzi F, Simpson E, Goldman JM, Melo JV, Lechler RI, Bellantuono I , Ridley A et al (2003) Dendritic cells from CML patients have altered actin organization, reduced antigen processing, and impaired migration.. Blood, 101(9), 3560-3567.
Bellantuono I, Gao L, Parry S, Marley S, Dazzi F, Apperley J, Goldman JM & Stauss HJ (2002) Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL.. Blood, 100(10), 3835-3837.
Campagnoli C (2002) High transduction efficiency of circulating first trimester fetal mesenchymal stem cells: potential targets for in utero ex vivo gene therapy. BJOG: An International Journal of Obstetrics and Gynaecology, 109(8), 952-954.
Campagnoli C, Bellantuono I, Kumar S, Fairbairn LJ, Roberts I & Fisk NM (2002) High transduction efficiency of circulating first trimester fetal mesenchymal stem cells: potential targets for in utero ex vivo gene therapy.. BJOG, 109(8), 952-954.
Baxter MA, Wynn RF, Deakin JA, Bellantuono I, Edington KG, Cooper A, Besley GTN, Church HJ, Wraith JE, Carr TF & Fairbairn LJ (2002) Retrovirally mediated correction of bone marrow-derived mesenchymal stem cells from patients with mucopolysaccharidosis type I.. Blood, 99(5), 1857-1859.
Campagnoli C, Roberts IA, Kumar S, Bennett PR, Bellantuono I & Fisk NM (2001) Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow.. Blood, 98(8), 2396-2402.
Campagnoli C, Fisk NM, Kumar S, Bellantuono I, Bennett PR & Roberts IAG (2000) Identification of mesenchymal stem cells in human first trimester fetal blood, liver and bone marrow.. BLOOD, 96(11), 279A-279A.
Bellantuono I, Macchiarulo E, Gao LQ, Dazzi F, Cerundolo V, Marley SB, Gordon MY, Goldman JM & Stauss HJ (2000) Immunoresponse to Wilms Tumor antigen-1 (WT-1) in CML patients.. BLOOD, 96(11), 144A-144A.
Bellantuono I, Lashford LS, Rafferty JA & Fairbairn LJ (2000) The expression of full length Gp91-phox protein is associated with reduced amphotropic retroviral production.. Haematologica, 85(5), 451-457.
Gao L, Bellantuono I, Elsässer A, Marley SB, Gordon MY, Goldman JM & Stauss HJ (2000) Selective elimination of leukemic CD34+ progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood, 95(7), 2198-2203.
Gao L, Bellantuono I, Elsässer A, Marley SB, Gordon MY, Goldman JM & Stauss HJ (2000) Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1.. Blood, 95(7), 2198-2203.
Bellantuono I, Gao L, Elsaesser A, Marley S, Gordon M, Goldman J & Stauss H (1999) Selective elimination of leukemic progenitors by allorestricted CTL specific for Wilms tumor antigen-1 (WT-1).. BLOOD, 94(10), 532A-533A.
Fairbairn LJ, Lashford LS, Spooncer E, McDermott RH, Lebens G, Arrand JE, Arrand JR, Bellantuono I, Holt R, Hatton CE , Cooper A et al (1997) Towards gene therapy of Hurler syndrome.. Cas Lek Cesk, 136(1), 27-31.
Fairbairn LJ, Lashford LS, Spooncer E, McDermott RH, Lebens G, Arrand JE, Arrand JR, Bellantuono I, Holt R, Hatton CE , Cooper A et al (1996) Long-term in vitro correction of alpha-L-iduronidase deficiency (Hurler syndrome) in human bone marrow.. Proc Natl Acad Sci U S A, 93(5), 2025-2030.
ALESSANDRINO EP, BERNASCONI P, BONFICHI M, CALDERA D, BONI M, BELLANTUONO I, BIAGGI G & BERNASCONI C (1993) TREATMENT OF HIGH-RISK LEUKEMIA WITH BUSULFAN, CYCLOPHOSPHAMIDE, ETOPOSIDE AND ALLOGENEIC BONE-MARROW TRANSPLANTATION. EXP HEMATOL, 21(8), 1132-1132.
CASTAGNOLA C, BONFICHI M, BELLANTUONO I, BRERA C, ALESSANDRINO EP, POLATTI F, ZARA C & BERNASCONI C (1993) GROWTH OF HEMATOPOIETIC PROGENITOR CELLS DERIVED FROM UMBILICAL-CORD BLOOD. EXP HEMATOL, 21(8), 1137-1137.
Morsli S, Henriques CM, Ellis PS, Mortiboys H, Baxendale S, Loynes CA, Renshaw SA & Bellantuono I () A p21‐GFP zebrafish model of senescence for rapid testing of senolytics in vivo. Aging Cell.
Pickering GAE, Felix-Ilemhenbhio F, Clark MJ, Kocsy K, Simpson J, Bellantuono I, Gartland A, Wilkinson JM, Hatzikotoulas K & Kiss-Toth E () The Kinesin Gene KIF26B Modulates the Severity of Post-Traumatic Heterotopic Ossification. International Journal of Molecular Sciences, 23(16), 9203-9203.
Chen Z, Cordero J, Alqarni AM, Slack C, Zeidler MP & Bellantuono I () Zoledronate extends healthspan and survival via the mevalonate pathway in a FOXO-dependent manner. The Journals of Gerontology: Series A.
Oliviero S, Roberts M, Owen R, Reilly GC, Bellantuono I & Dall’Ara E () Non-invasive prediction of the mouse tibia mechanical properties from microCT images: comparison between different finite element models. Biomechanics and Modeling in Mechanobiology.
Soriano-Arroquia A, Gostage J, Bardell D, McCloskey E, Bellantuono I, Clegg P, McDonagh B & Goljanek-Whysall K () miR-24:Prdx6 interactions regulate oxidative stress and viability of myogenic progenitors during ageing.
Hatzikotoulas K, Pickering GAE, Clark MJ, Felix-Ilemhenbhio F, Kocsy K, Simpson J, MacInnes SJ, Koprulu M, Southam L, Bellantuono I , Baidžajevas K et al () Genome-wide association and functional analyses identify CASC20 and KIF26B as target loci in heterotopic ossification.
Chen Z, Cordero J, Slack C, Zeidler M & Bellantuono I () Zoledronate extends healthspan and survival via the mevalonate pathway in a FOXO-dependent manner.

Chapters

Bellantuono I & Fairbairn L (2006) Adult Stem Cells and Gene Therapy, Tissue Stem Cells (pp. 305-337). CRC Press
Stauss H, Bellantuono I, Hsu S & Ramirez F (2004) Tumour immunology, Infection and Immunity (pp. 109-122). CRC Press

Conference proceedings papers

Martins RR, Ellis P, Mughal N, Bellantuono I & Henriques CM (2019) Abstract # 3231 Telomerase-dependent senescence and inflammation with ageing in the zebrafish brain. Brain, Behavior, and Immunity, Vol. 81(Supplement) (pp 7-7). Berlin, Germany, 4 June 2019 - 8 June 2019. View this article in WRRO
Misra J, Misra J, Mohanty ST, Madan S, Fernandes JA, Ebetino FH, Roehl H, Russell RG & Bellantuono I (2013) Can Bisphosphonates extend Life Span? Effects on Stem Cell survival, DNA Repair and Tissue Regeneration. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 28
Wang QG, Mohanty S, Bellantuono I & Gartland A (2012) TIBIAL PLATEAU BONE SURFACE ROUGHNESS - A POTENTIAL NEW EARLY MARKER TO DETECT ARTHRITIS?. OSTEOPOROSIS INTERNATIONAL, Vol. 23 (pp S574-S574)
Bellantuono I, Cairney C, Sanguinetti G, Ranghini E, Nostro MC, Bhattacharya A, Svendsen CN & Keith WN (2009) A system biology approach to Down Syndrome: identification of Notch/Wnt dysregulation in stem cells with age. JOURNAL OF MEDICAL GENETICS, Vol. 46 (pp S22-S22)
Suzuki M, McHugh J, Tork C, Shelley B, Hayes A, Bellantuono I, Aebischer P & Svendsen CN (2008) Intramuscular delivery of GDNF with human mesenchymal stem cells protects dying motor neurons and prolongs survival in a rat model of familial ALS. CELL TRANSPLANTATION, Vol. 17(4) (pp 482-483)
Holmes KD, Bellantuono I, Walkinshaw SA, Alfirevic Z, Johnston T, Subhedar NV, Chittick R, Swindell R & Wynn RF (2005) Human fetal haematopoietic stem cells show different telomere length dynamics from age-matched post natal stem cells in a longitudinal study. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 129 (pp 8-8)
Holmes DK, Bellantuono I, Walkinshaw SA, Alfirivec Z, Johnston TA & Wynn RF (2003) Human fetal hematopoietic stem cells show different telomere length dynamics to post natal and adult blood cells in a longitudinal study.. BLOOD, Vol. 102(11) (pp 566A-566A)

Datasets

Dall'Ara E, Oliviero S, Reilly G, Bellantuono I & Owen R Data for the paper: "Optimization of the failure criterion in micro-Finite Element models of the mouse tibia for the non-invasive prediction of its failure load in preclinical applications".

Preprints

Morsli S, Henriques C, Ellis PS, Mortiboys HJ, Baxendale S, Loynes CA, Renshaw S & Bellantuono I (2022) A p21-GFP zebrafish model of senescence for rapid testing of senolytics in vivo., Cold Spring Harbor Laboratory.

Research group

Current Collaborators

Paul Potter
Infrafrontier Network
Keye Williams
Paul Potter
Rafael De Cabo
Tamara Tchakonia
Dudley Lamming

PhD Students

Jeremy Richard (primary supervisor)
John Gostage
Luke Mansfield
Raquel Martins (secondary supervisor)

Teaching interests

Until 2017 I was the Director of training for the MRC-AR UK Centre for Integrated research into Musculoskeletal Ageing (CIMA). The Centre is a is a collaboration between the Universities of Liverpool, Newcastle and Sheffield and the training includes an MRes and PhD programme.

I also contribute to the Student Selected Components of Phase 1a of the MBChB course.

Professional activities and memberships

Most of my time is now taken by getting the Healthy Lifespan Institute (https://www.sheffield.ac.uk/healthy-lifespan) up and running. This has been built from my experience when I have Chaired and led the effort of the COST Action MouseAGE (https://www.mouseage.eu/) a European network comprising over 200 researchers from 25 EU countries to identify a roadmap to take medicinal drugs targeting mechanisms of ageing (geroprotectors) to the patients.

Until recently I headed the Mellanby Centre skelet.AL laboratories (former Bone Analysis Laboratory), which provides access and expertise to contemporary technologies for the analysis of bone to investigators, internally and externally.

I was also the Director of Research for the Department of Oncology and Metabolism and a member of the Faculty Research and Innovation Committee, which oversees the Faculty strategic approach to Research and Innovation. At present I am serving as a panel member for the UKRI Future Leader Fellowship scheme.

I have been the Chair of the BBSRC Bioscience Skills and Careers (BSC) Strategy Advisory Panel, The BBSRC Fellowship portfolio monitoring group and a member of BBSRC Research Advisory Panel, roles I have enjoyed enormously and from which I have gained experience in policymaking in the vital skills and science sector.

I have taken part in evaluation of funding for NC3Rs, Arthritis Research UK and Horizon 2020 panels